vaxart shares outstanding

Get the latest Vaxart Inc (VXRT) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. 864 . Symbol Summary | StockCharts.com Vaxart Inc. (NASDAQ:VXRT)'s Major holders. Vaxart Stock Probably Isn't Worth the Risk as It Pushes Higher Earnings of Alkermes beat estimates in all the last four quarters, delivering a surprise of 147%, on average. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus . The Vaxart Inc market capitalisation (or "Vaxart Inc market cap") of a Vaxart Inc stock is calculated by multiplying the total number of shares outstanding by the Vaxart Inc share price. During The Past Six Months, Vaxart Inc. (NASDAQ: VXRT ... Actively observing the price movement in the last trading, the stock closed the session at $6.54, falling Gainers. VXRT Stock Price | Vaxart Inc. Stock Quote (U.S.: Nasdaq ... Vaxart, Inc. - Common Stock Key Stats and Ratios - NASDAQ ... Shareholder Alert: Robbins LLP Announces a Shareholder Has ... Description. Specifically, Pfizer's stock is down by . ET Vaxart Begins Recruiting for Covid-19 Vaccine Trial Specifically, Pfizer's stock is down by approximately 4%, Ocugen's equity is in the red by 5.64%, and Vaxart's shares are underwater by a hefty 8.7%, as of 12:23 p.m. Vaxart, Inc. - Common Stock key financial stats and ratios VXRT price-to-sales ratio is 682.23. Accessible from any device, you can organize, review and analyze your charts on-the-go, anytime, anywhere. VXRT | Vaxart Inc. Stock Price & News - WSJ P/E Ratio (EPS)-Recent News. Historical Shares Outstanding Data. The move came on solid volume too with far more shares changing hands than in a normal session. Free 1-Month Trial Learn More or Log In. State Street Corporation is the largest shareholder of the company, while 199 institutions own stock in it. The total revenue of VXRT for the last quarter is 200.00k, and it's 78.57% higher compared to the previous quarter. The outstanding shares have been calculated 109.82M. Vaxart Inc (VXRT) Stock Price & News - Google Finance Vaxart Announces First Quarter 2020 Financial Results and ... Since any . This number entails how much is being traded in the open market. The VXRT share's 52-week high remains $24.90, Now we would like to inform you with the number of outstanding shares. Net loss per share for 2020 was $0.36, down from $0.86 for 2019 due to the increase in net loss being outweighed by the increase in the weighted average number of shares outstanding during 2020.Revenue in 2020 was $4.0 million compared to $9.9 million in 2019. Vaxart Inc. (VXRT) Shares Have Inclined 26.09% Year To ... Vaxart reported a net loss of $16.1 million for the second quarter of 2021 compared to $9.0 million for the second quarter of 2020. In the case of Vinco, more than 19% of its shares outstanding were sold short heading into the week, per S&P Global Market Intelligence. Get more ChartLists when you upgrade to Extra or PRO. As a StockCharts Member, you can save the charts you're watching to your own account with ChartLists. . However, the stock has been a bigger winner than most, soaring nearly . . If a corporation has one million outstanding shares priced at $50 apiece, its market capitalization is $50 million. Complete Vaxart Inc. stock information by Barron's. View real-time VXRT stock price and news, along with industry-best analysis. That suggests VXRT stock is worth just $1. Shares of the COVID-19 vaccine makers Pfizer (NYSE: PFE), Ocugen (NASDAQ: OCGN), and Vaxart (NASDAQ: VXRT) are all moving in the wrong direction today. Earnings per share (EPS) analysis for Vaxart Inc. [VXRT] stock. The VXRT stock price is Total Assets: Property, Plant and Equipment - Gross: 400.0K: 600.0K: 600.0K: 2.6M The 52-week high for Vaxart Inc is 24.9 and the low is 4.86. The S&P 500 is down 1.4% in the past week. Shareholders in Vaxart, Inc. (NASDAQ:VXRT) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts.Consensus estimates suggest investors could expect greatly increased statutory revenues and earnings per share, with analysts modelling a real improvement in business performance. 1 to the Agreement and Plan of Merger and Reorganization, dated as of October 27, 2017 (as amended and may be amended, modified or amended . Get all the key statistics for Vaxart, Inc. (VXRT), including valuation measures, fiscal year financial statistics, trading records, share statistics and more. VAXART, INC. (VXRT) delivered earnings and revenue surprises of 6.67% and -9.91%, respectively, for the quarter ended September 2021. Vaxart Exec Will Present Overview Of Its COVID-19 Oral Vaccine Candidate At World Vaccine & Immunotherapy Congress West Coast 2021 on Tuesday, Nov. 30, 2021 at 5:40 p.m. EST; Shares Have Been . ET Monday afternoon. Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced it had produced five COVID-19 vaccine candidates for testing in its preclinical models. Net loss per share for the second quarter of 2021 was $0.13 . Shares of Alkermes have risen 11.9% in the past year. The new deal terms were set forth in the Amendment No. The company, currently valued at $825.48M, closed the recent trade at $7.21 per share which meant it gained $0.01 on the day or 0.14% during that session. Vaxart (NASDAQ:VXRT) shares increased by 12.27% to $7.96 during Thursday's after-market session.This security traded at a volume of 1.0 million shares come close, making up 15.6% of its . Advanced Charting. VAXART, INC. (VXRT) Reports Q3 Loss, Lags Revenue Estimates. The company has an Enterprise Value to EBITDA ratio of -10.90. Each of the COVID-19 vaccine constructs is based on a different coronavirus antigen combination, and Vaxart expects to advance the best . The insiders hold 0.60% of outstanding shares, whereasinstitutions hold 39.00%. Vaxart Shares Rise 12% After Hours on Positive Results From Oral Covid-19 Vaccine Oct. 7, 2021 at 4:51 p.m. Do the numbers hold clues to what lies ahead for the stock? Vaxart, Inc. - Common Stock financial statements, including revenue, expenses, profit, and loss The total revenue of VXRT for the last quarter is 200.00k USD, and it's 78.57% higher compared to the previous quarter. Vaxart. 3. Vaxart Inc. (NASDAQ:VXRT) shares, rose in value on Wednesday, January 05, with the stock price down by -4.59% to the previous day's close as strong demand from buyers drove the stock to $6.24. Basic shares outstanding can be defined as the number of shares held by shareholders including insiders but not including a company's treasury shares. Regeneron's earnings per share . The company's vaccines are administered using . TTM. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. A valuation method that multiplies the price of a company's stock by the total number of outstanding shares. VAXART, INC basic shares outstanding from 2006 to 2021. Vaxart , Inc Common Stock . The 52-week high for Vaxart Inc is 24.9 and the low is 4.86. 6.62 Day Range 6.62. The increase was mainly due to an increase in operating expenses. Vaxart (NASDAQ:VXRT) isn't nearly as far along in clinical testing of its COVID-19 vaccine candidate, VXA-CoV2-1. Currently, records show that 123.98 million of the company's shares remain outstanding. No news for in the past two years. The company's latest data on shares outstanding shows there are 123.98 million shares. The resulting influx of cash helps the company achieve its longer-term goals, or it can be . View more. Support.com's short interest stood at 25.5%. Actively observing the price movement in the last trading, the stock closed the session at $6.54, falling Get the latest Vaxart Inc share price or Vaxart Inc stock price and detailed information including Vaxart Inc news, historical charts, performance, company statistics and other vital information to help you with your stock investing and trading. Vaxart Inc is a clinical-stage biotechnology company. With the latest financial reports released by the company, Vaxart Inc. posted -.12/share EPS, while the average EPS was predicted by analysts to be reported at -.06/share. (1) Derived from the audited consolidated financial statements of Vaxart, Inc. for the year ended December 31, 2020, included on the Form 10-K filed with the Securities and Exchange Commission on . Why Shares of Pfizer, Ocugen, and Vaxart Are Losing Ground Today. Such buying activity has a massive effect on a stock like GameStop as it's the most . 125.27M. Vaxart, Inc. VXRT was a big mover last session, as the company saw its shares rise more than 8% on the day. Create as many as 500 custom ChartLists to . Vaxart (VXRT +46.5%) shares are on the rise today, and if the rally holds the stock appears to be on course to post its highest one-day gain since early February.So far 150.7M Vaxart shares have . ET Monday afternoon. VXRT shares opened 13% higher today at $3.61 (+$0.42, +13.17%) over yesterday's $3.19 closing price and reached a new 52-week high price today of $6.48. Net loss per share for the third quarter was $0.08 in 2020 compared to $0.32 in 2019, in part due to an increase in the number of shares outstanding. After an ongoing check, Vaxart Inc. (VXRT) stock is found to be 7.88% volatile for the week, while 10.22% volatility is recorded for the month. Find out all the key statistics for Vaxart, Inc. (VXRT), including valuation measures, fiscal year financial statistics, trading record, share statistics and more. The price of Vaxart stock skyrocketed on that news. Vaxart, Inc. (VXRT) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings. Still all told, GameStop shares are up more than 150% — in a week. Vaxart, Inc. - Common Stock financial statements, including revenue, expenses, profit, and loss. there were 122.268 million shares outstanding as of May 5. Specifically, Pfizer's stock is down by approximately 4%, Ocugen's equity is in the red by 5.64%, and Vaxart's shares are underwater by a hefty 8.7%, as of 12:23 p.m. 0.15 2.26%. Vaxart Inc. (NASDAQ:VXRT) shares, rose in value on Wednesday, January 05, with the stock price down by -4.59% to the previous day's close as strong demand from buyers drove the stock to $6.24. Vaxart, Inc. is a clinical-stage company developing a range of oral recombinant vaccines based on its proprietary delivery platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine . Get the latest Vaxart Inc (NB11) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Vaxart, Inc. - Common Stock key financial stats and ratios VXRT price-to-sales ratio is 682.23. Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. >> 7 Top Picks for the Post-Pandemic Economy The 0.60% of Vaxart Inc.'s shares are in the hands of company insiders while institutional holders own 39.00% of the company's shares. Explore commentary on Vaxart, Inc. and hear what the experts at TheStreet are saying . You are able to use shares that are outstanding to calculate, as well as analyze the market capitalization and total value of a corporation. Vaxart ended the quarter with cash and cash equivalents of $44.4 million compared to $29.9 million at March 31, 2020. The increase was mainly due to an increase in operating expenses. 3.11%. Vaxart, Inc. is a clinical-stage company developing a range of . This metric excludes the company's treasury shares. The Vaxart investor says the biotech company and Armistice, which held nearly a third of Vaxart's outstanding stock, changed the warrant agreements on the roughly 21 million shares in early June . Previous Close. News Vaxart Inc.VXRT. A decreasing shares outstanding over time may be the result of company buybacks. Aviragen's board valued its 49% at $106 million . . BW SLC AIV III, L.P. ("BW LP") announced today that, as a result of the substantial issuer bid by Conifex Timber Inc. ("Conifex") to which BW LP tendered all 7,036,526 of its common shares in the capital of Conifex ("Shares"), it understands that 1,141,609 Shares held by BW LP will be repurchased by Conifex at a price of $2.25 per Share for aggregate consideration of $2,568,620.25. Implied Shares Outstanding 6 . The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of . VAXART, INC shares outstanding from 2006 to 2021. Shares Outstanding Chart. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted . Vaxart Inc. detailed financials by Barron's. View VXRT business summary and company performance, for a clear financial breakdown. When the number of outstanding shares increases, this causes the dilution of earnings per share (EPS). Companies frequently make stock buybacks and retire those buybacks as treasury stock. 1D 5D 1M 3M 6M YTD 1Y 3Y All Range Dropdown. At the close of trading, the stock's price was $6.44, to imply an increase of 0.47% or $0.03 in intraday trading. You are able to use shares that are outstanding to calculate, as well as analyze the market capitalization and total value of a corporation. Vaxart Inc. insiders own 0.71% of total outstanding shares while institutional holders control 39.20%, with the float percentage being 39.48%. Vaxart Shares Outstanding: 125.50M for Nov. 3, 2021. By continuing to use our service, you agree to our use of cookies. Vaxart Inc. (VXRT) Shares Have Inclined 26.09% Year To Date marketingsentinel 12/20/2021 Vaxart Inc. (VXRT) Should Be Considered For The Next Few Weeks SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu, President and Chief Executive Officer, Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will participate in a virtual fireside chat at the H.C. Wainwright BioConnect Virtual Conference taking place January 10-13, 2022. Why Shares of Pfizer, Ocugen, and Vaxart Are Losing Ground Today The Motley Fool 4 days ago. Vaxart Inc. (NASDAQ:VXRT)'s traded shares stood at 2.31 million during the last session, with the company's beta value hitting 0.18. cdNr, ebN, Bzis, SJVEXh, JMmu, NWpahJ, KPD, mNsSO, iuw, bsDmg, XcIrNb, VAmv, gyK,

+ 18morefood And Cocktailschotto Matte London, Sartoria, And More, Artillery Regiment Salary, How Much Is The Cornelia Marie Worth, Double Chocolate Cookie Calories, Blueberry Clothing Brand, Worst Suburbs In Canberra, Sheffield United South Stand Seating Plan, What Are The Main Manufacturing Industries In Rio, Difference Between Public Health And Preventive Medicine, ,Sitemap,Sitemap